Key result
Current AHA/ATS pediatric PH guidelines rely on Level B evidence despite a historical ~10-month survival.
This review highlights the diagnostic challenges in pediatric pulmonary hypertension and the reliance on Level B evidence in current guidelines.
Current AHA/ATS pediatric PH guidelines warrant cautious use given Level B evidence; leaves open need for stronger data to improve survival.
As with any rare disease, a low prevalence in the population is a setup for missed diagnosis. Pulmonary hypertension (PH) can occur at any age during childhood and like in adults, a delay in diagnosis is common.1 Historical outcomes for idiopathic pulmonary arterial hypertension are worse than adults, with a mean survival of 10 months after diagnosis.2 This highlights the need for accurate workup for a potential pediatric PH diagnosis. Generally the evaluation process has paralleled the adult guidelines.34 However, adult guidelines lack evidence-based support in pediatrics.5 Recently the American Heart Association and American Thoracic Society created guidelines for the diagnosis and management of pediatric PH.6 The guidelines offer a diagnostic algorithm needed to verify the diagnosis and work up potential etiologies (Figure 1). They provide the best evidence-based support for the workup and rationale involved. However, the guidelines are still hindered in that the majority of the evidence to support them is Level B (data derived from limited populations)6 (Table 1). This review will discuss some of the diagnostic challenges in pediatric PH.
No takes yet. Share an insight, caveat, or question.
Edward C. Kirkpatrick (2016) conducted a review in Pediatric Pulmonary Hypertension. Diagnostic evaluation of pediatric pulmonary hypertension relies on recent AHA/ATS guidelines, which are limited by Level B evidence for a disease with a historical mean survival of 10 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: